Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study

Journal of Clinical Pharmacology

Volumn 37, Issue 12, 1997, Pages 1114-1120

  Loi, Cho Ming ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; QUINONE DERIVATIVE; SULFATE; TROGLITAZONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SULFATION; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION;

EID: 0031406407     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04295.x     Document Type: Article

References (16)

1. Horikoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi K, Sasahara K: Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab 1994;46:l-57.
2. Lebovitz HE, Feinglos MN: Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1987;1:189-198.
3. Bailey CJ, Turner RC: Metformin. NEnglJMed 1996:334:574-579.
4. Ciaraldi TP, Gilmoro A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a now antidiabetic agent. Metabolism 1990;39:1056-1002.
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studios in KK and ob/ob Mice and Zucker fatty rats. Diabetes 1988:37:1549-1558.
6. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabotic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Core 1991;14:1083-1086.
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olofsky JM: Metabolic effects of new oral hypoglycémie agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15:192-203.
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl} Med 1994;331:1188-1193.
9. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y: Prediction of the human pharmacokinetics of troglitazone, a now and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996;277:1630-1641.
10. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979:28:1039-1057.
11. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekkar, 1982.
12. Gwilt PR, Nahhas RR, Tracewell WG: The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991;20:477-490.
13. Zysset T, Wietholtz H: Differential effect of type I and type II diabetes on antipyrine disposition in man. Ear J Clin Pharmacol 1988;34:369-375.
14. Zysset T, Wietholtz H: Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus. EurJClin Pharmacol 1991:41:449-452.
15. Adithan C, Sriram G, Swaminathan RP, Krishnan M, Bapna JS, Chandrasekar S: Effect of type II diabetes mellitus on theophylline elimination. IntfClin Pharmacol Ther Toxicol 1989; 27:258-260.
16. Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR: Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997;37:1038-1047.